Characterizing mechanisms of sensitivity and resistance to anti-androgen therapy with whole-body molecular imaging.
Recruiting
- Conditions
- metastatic castration-resistant prostate cancer
- Registration Number
- NL-OMON26005
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Histologically confirmed prostate cancer adenocarcinoma
2. Eligible for abiraterone treatment as judged by the treating physician.
3. Castrate levels of serum testosterone
4. Progressive disease manifest by either imaging (bone imaging, MRI, CT, or PSMA PET-CT) or biochemical progression (PSA).
5. Visible lesions on CT, bone imaging, MRI, or PSMA PET-CT consistent with disease.
Exclusion Criteria
1. Previous anaphylactic reaction to either FDHT or PSMA.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method